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What is the nature of asthma and where are the 
therapeutic targets? 
P. H. HOWARTH 
University Medicine, Southampton General Hospital, U.K. 
The characterisation of chronic asthma as an inflammatory condition of the human airway, associated 
with heightened airway responsiveness to a variety of bronchial stimuli, has lead to the clarification of 
therapeutic strategies. These strategies have focused on bronchodilation and attenuation of airway 
inflammation. Inhaled corticosteroids effectively reduce chronic inflammation and produce substantial 
symptomatic relief in most patients. This article examines the pathophysiology of asthma and discusses 
the interpretation of current methods of assessment, and the targets and actions of inhaled anti- 
asthmatic drugs in relationship to central and peripheral airway events. 
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Introduction 
Asthma is a chronic airway disease characterised by 
episodic wheezing, coughing and chest tightness 
associated with airflow obstruction. For many years, 
asthma was regarded as a disease involving abnormal 
contractility of airway smooth muscle and thus solely 
treated with bronchodilator medication. However, 
improved understanding of the disease process has 
altered this perception, such that asthma is now 
regarded primarily as an inflammatory airway dis- 
order. This realisation has led to consequent changes 
in the approach to therapy and therapeutic targets, 
with the recommended prophylactic use of anti- 
inflammatory therapy (1). Mast cells, eosinophils, 
epithelial cells and lymphocytes are implicated as 
central to the disease process, while at the molecular 
level, numerous inflammatory mediators, cytokines, 
chemokines, adhesion molecules and transcription 
factors have received widespread attention. Despite a 
greatly improved understanding of the pathogenesis 
of asthma, there are still many aspects which remain 
to be fully elucidated, not least of these being the 
relative contribution of inflammation in the large 
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and small airways to clinical disease expression. 
This review examines the interpretation of current 
methods of assessing asthma, details the inflam- 
matory process, and discusses the targets and actions 
of inhaled anti-asthmatic drugs in relationship to 
large and small airway events. 
Pathophysiology of Asthma and Chronic 
Obstructive Pulmonary Disease 
Assessment of airway obstruction 
Objective measurements of airflow obstruction can be 
obtained by lung function tests. Many measurement 
techniques are available, including, for example, body 
plethysmography and flow volume loops, as well as 
spirometry and peak expiratory flow. For clinical 
purposes, simple peak flow monitoring with a hand- 
held peak flow meter is most commonly used to assess 
airflow obstruction, either as a reduced peak expira- 
tory flow rate (PEFR) or as an exaggerated diurnal 
variation in peak flow. More formal lung function 
testing requires spirometry, to measure the percent- 
age reduction in the volume of air exhaled during the 
first second of forced expiration (FEV,), or a reduc- 
tion in the ratio of FEV, to forced vital capacity 
(FVC). An indication of what is represented by these 
parameters can be obtained from examining the 
changes in cross-sectional areas in different parts of 
the airway, which vary from lo6 cm2 at the alveolar 
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FIG. 1. Illustration of how bronchial hyperresponsiveness may be linked to airway wall thickening. Adapted 
from Ref. 2. 
level down to 3 cm2 in the trachea. The trachea is thus 
the major site of airflow limitation, and changes here 
will be reflected by the peak flow rate. Although 
FEV, reflects events in both large and small airways, 
it is widely recognised that much loss of small airway 
function is silent and does not influence lung function 
measurements. It can be demonstrated mathemati- 
cally that large percentage changes in peripheral 
resistance have relatively little impact on airways 
resistance and thus, by implication, on peak flow and 
FEV, measurements. Both parameters are therefore 
unreliable reflections of events in the small airways. 
The criteria for small airway obstruction are abnor- 
mal ventilation-distribution, combined with normal 
elastic and flow-resistive properties, and density- 
independence of maximal expiratory flow and flow 
resistance. A simple parameter such as FVC may 
provide information on gas trapping which frequently 
accompanies small airway disease, but will also be 
modified by changes in lung volume and may thus be 
misleading (2). 
Density dependence has been used to assess sites 
of airflow obstruction. It is a difficult and often 
unreliable technique, based on airflow in the large 
airways being turbulent, and therefore density depen- 
dent, whereas the slower flow in small airways is 
laminar and density independent, A change in density 
of the inspired air, such as breathing an 80”/0 helium 
mixture, will alter the measurements of resistance and 
can be used to partition resistance between the large 
or small airways. Measurements of this type made 
on smokers and non-smokers in the late 1960s (2) 
indicated that in smokers, obstruction in the small 
airways predominated, whereas in non-smokers, 
uncomplicated obstructive airway disease was mostly 
associated with the large airway events. In patients 
who suffered recurrent episodes of infection, both 
sites were found to be affected. 
Ventilation scans provide an alternative way of 
assessing small airway obstruction. Such scans indi- 
cate that in asthma, much greater aerosol deposition 
occurs in central airways relative to peripheral air- 
ways, suggesting a defect in small airways ventilation. 
Similar results have been obtained from penetration 
indices (ratio of central airway deposition to peri- 
pheral airway deposition) determined from planar 
imaging. Studies of this type suggest that small air- 
ways disease is a feature of asthma, and that the 
simple measurements of lung function used clinically, 
focus more on large airway events and improvements 
in these parameters may not be reflected by small 
airway pathology. 
Structural changes to the airway: distribution 
and relationship to bronchial 
hyperresponsiveness 
Structural changes that could contribute to possible 
airflow defects are known to occur throughout the 
airways of asthmatics, being evident in large and 
small (~2 mm internal perimeter)airways (3,4). These 
include sub-epithelial fibrosis with increased 
deposition of type III and IV collagen, smooth 
muscle hyperplasia and hypertrophy, and neo- 
vascularisation, which together contribute to thicken- 
ing of the airway wall. The importance of this 
thickening has been highlighted by mathematical 
modelling (5), which suggests that it may contribute 
to the increased bronchoconstrictor response to 
inhaled stimuli (bronchial hyperresponsiveness) by 
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disproportionately reducing the size of the airway 
lumen during smooth muscle contraction (Fig. 1). In 
large airways, the radius of the lumen will not be 
dramatically affected by thickening of the airway 
wall, nor will the airflow (which is inversely propor- 
tional to l/radius4), whereas comparable changes in 
small airways will have a much greater impact. These 
structural changes to the airway wall, which are 
clearly visible in electron micrograph studies of 
biopsy specimens from asthma patients, are thought 
to be the result of exaggerated repair processes occur- 
ring in response to inflammatory cell recruitment and 
tissue damage. 
A number of fibrogenic mediators have been ident- 
ified which could be implicated in this repair process 
(6). These include growth factors such as transform- 
ing growth factor beta (TGF-p), platelet-derived 
growth factor (PDGF) and basic fibroblast growth 
factor (BFGF), cytokines such as interleukins 1 and 4 
(IL-l, IL-4), tumour necrosis factor alpha (TNF-a), 
and mediators such as endothelin, histamine and 
tryptase. Many of these factors have been shown to 
be increased in bronchoalveolar lavage samples 
recovered from asthmatic airways and will reflect 
inflammatory events including mast cell degranula- 
tion, T-lymphocyte activation, epithelial cell activa- 
tion, eosinophil influx and indirect interaction 
between eosinophils and the airway matrix. Proteo- 
glycan molecules are a component of this matrix and 
consist of a central protein core to which sulphated 
glycosaminoglycan (GAG) side-chains are attached. 
These side-chains bind to, and inactivate, cytokines, 
so that the proteoglycan molecules function as 
cytokine storage sites. TGF$ also has a close rela- 
tionship with the matrix protein, decorin. TGF-/I 
induces synthesis of this protein, which in turn binds 
and inactivates the /31, /32 and p3 isoforms of TGF-P, 
providing a depot of this potent growth factor within 
the matrix layer. GAG side-chains can be cleaved 
from the protein core by enzymes, particularly 
metalloproteases and heparinases. The metallo- 
protease MMP-9, which co-localises to eosinophils, 
has been implicated in this process from in vitro 
studies. Migration of eosinophils through the airway 
epithelium and underlying proteoglycan scaffold of 
the submucosa, during leucocyte recruitment, may 
thus bring about local release of growth factors such 
as TGF-P. BFGF is also proteoglycan-bound and 
may be released by a similar process, thus implicating 
eosinophils indirectly in fibroblast proliferation. 
Leucocytp recruitment and airway inflammation 
The recruitment of leucocytes from the circulation to 
the tissues is a central feature of the inflammatory 
response, in which the vascular endothelium is recog- 
nised as having an important role (7). The initial stage 
of recruitment is ‘rolling margination’, during which, 
leucocytes from the bloodstream are slowed down 
under the influence of the adhesion molecules (adhes- 
ins) P- and E-selectin, expressed on the endothelial 
cell surface. Preformed P-selectin is stored intracellu- 
larly in Weibel-Palade bodies, from where it is rapidly 
mobilised by inflammatory mediators such as hista- 
mine or platelet-activating factor (PAF), whereas 
E-selectin is up-regulated by cytokines including 
TNF-/I and IL-lp. As leucocytes become marginated, 
they interact with chemokines such as interleukin-8 
(IL-S), macrophage inflammatory protein la (MIP- 
la) and RANTES presented on the glycocalyx, which 
mediate cell activation and increase expression of 
binding ligands such as leucocyte function-associated 
molecule-l (LFA-l), and other proteins, including 
metalloproteases. The newly expressed ligands 
increase adhesion by binding firmly to adhesion mol- 
ecules from the immunoglobulin supergene family, 
e.g. intercellular adhesion molecule- 1 (ICAM- l), vas- 
cular cell adhesion molecule-l (VCAM-l), present on 
the endothelial surface. In this context, the inter- 
action that occurs in allergic inflammation between 
the ligand, very late antigen-4 (VLA-4) and VCAM-1 
is of particular interest, as VLA-4 is expressed on 
eosinophils, lymphocytes and basophils, but not on 
neutrophils, and thus confers some specificity for cell 
recruitment. In contrast, LFA-l-ICAM inter- 
actions are non-selective, being common to all leuco- 
cytes, including neutrophils. Regulation of expression 
of VCAM-1 is also interesting as it is not only 
influenced by the cytokines, TNF-a and IL-l@, which 
affect many aspects of adhesion expression, but is 
upregulated by IL-4 and IL-5. These cytokines are 
characteristic of T,2 lymphocytes, which are also 
associated with allergic inflammation, and implicates 
them in a co-ordinating role in the allergic inflam- 
matory response. Hamid et al (8) have described 
up-regulation of mRNA for IL-3, IL-4, IL-5 and 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF) in bronchoalveolar lavage from asthma 
patients, and found IL-5 message co-localised to 
CD2+ cells, providing for evidence for upregulation 
of T,2-associated cytokines being consistent with 
expansion of a specific T-lymphocyte subpopulation. 
Once adhesion has occurred, cells diapedese 
through the inter-endothelial cell tight junctions and 
migrate through the tissue under the chemotactic 
influence of cytokines and chemokines, possibly 
facilitated by metalloproteases. IL-3, IL-5 and 
GM-CSF are thought to be particularly important 
in eosinophil recruitment and activation, as they 
stimulate proliferation and maturation of progenitor 
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FIG. 2. Schematic diagram illustrating the chemokines, chemoattractants and enzymes released by the 
epithelium following activation. 
cells in the bone marrow, enhance the response of 
eosinophils to other chemotactic stimuli, despite pos- 
sessing only weak intrinsic chemotactic activity, and 
prolong the survival of eosinophils in the tissues by 
inhibiting apoptosis. Post-mortem studies reveal that 
tissue eosinophilia is equally present in small and 
large airways in asthma and that large airway 
sampling will be reflective of small airway events (9). 
The role of epithelial cells 
Activated epithelial cells are recognised as an import- 
ant site for production of cytokines and chemokines, 
which affect recruitment of a variety of cells including 
macrophages and eosinophils. Chemokines are 
thought to regulate the movement of eosinophils after 
their initial attraction by IL-5. For example, the 
known eosinophil chemoattractant and activator, 
RANTES is expressed by epithelial cells, but atten- 
tion has also focused on IL-8, a classical neutrophil 
chemoattractant. A recent study using endobronchial 
allergen challenge (10) found that immunoreactive 
RANTES levels in lavage fluid increased at allergen 
challenge sites compared to control sites, and this 
correlated with eosinophil influx. In the case of IL-S, 
local release of IL-4 and tryptase can lead to forma- 
tion of an IL-&secretory IgA (sIgA) complex, which 
is a potent eosinophil chemoattractant and activator 
found at increased levels in asthma. This complex 
formation illustrates the duplicity of action among 
cytokines and the role of such interactions in 
modulating activity at the local level. Eotaxin is 
another candidate chemokine for study, and survival 
of eosinophils is also enhanced in the epithelium by 
production of GM-CSF. Enzymes such as inducible 
cycle-oxygenase (COX,) and inducible nitric oxide 
synthase (INOS), as well as the peptide, endothelin, 
are also produced by epithelial cells (Fig. 2). 
Endothelin is a potent bronchoconstrictor and a 
growth factor for fibroblasts, while iNOS mediates 
the production of nitric oxide (NO), a regulatory 
molecule that is thought to be generated in the lower 
airways and has been widely reported to occur in 
elevated levels in exhaled air from asthma patients. 
The influence of sampling techniques on disease 
assessment 
Both direct and surrogate markers for airway inflam- 
mation can be measured by current clinical proce- 
dures. For example, exhaled NO is a surrogate 
marker which may reflect epithelial activation. Direct 
measurements such as bronchial lavage, broncho- 
alveolar lavage and induced sputum, provide indices 
of luminal events, whereas biopsy reflects tissue 
events within the airways. These two compartments 
may be separate and give different information about 
the disease state. This is illustrated by recent corre- 
lation analyses, where comparisons between luminal 
mast cell numbers and lavage tryptase showed a 
correlation, whereas submucosal cells and lavage 
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FIG. 3. The influence of technique on the site of 
airway being sampled. 
did not. Similar observations have been made with The action of bronchodilators and location of 
eosinophil numbers and lavage ECP levels (11). receptors 
For luminal events, sampling techniques involve 
either a small wash of a proximal airway site via a 
bronchoscope (bronchial wash), or flooding the air- 
way with a larger volume to recover both proximal 
and distal airway samples (bronchoalveolar lavage). 
Bronchoscopic lavage of this type bypasses the larger 
airways above the bronchoscope, which are probably 
implicated in airway obstruction and induced sputum 
will provide a better measure of events in these areas 
(Fig. 3). The various sites of sampling give different 
information, as evidenced from a study by Fahy et al 
(12) comparing cell counts in samples taken from 
asthma patients (Table 1). In these studies, the 
highest counts of epithelial cells, and lymphocytes 
occurred in bronchial wash and bronchoalveolar 
lavage, respectively, whereas eosinophil numbers 
were highest in induced sputum. Induced sputum also 
A number of effective inhaled therapies for asthma 
act on different components of the disease process. 
Bronchodilators such as &agonists and anticholiner- 
gics interact with &adrenoceptors and muscarinic 
receptors, respectively, to bring about rapid sympto- 
matic relief. However, the distribution of these 
receptors varies. Muscarinic receptors occur almost 
exclusively in proximal airways, whereas 
P,-adrenoceptors are located on a variety of cells 
including smooth muscle, epithelial cells, Clara cells, 
mucous cells, endothelial cells, mast cells, T-cells, 
pneumocytes and autonomic ganglia, although they 
also are distributed to a higher degree in central 
airways (14). &agonists consequently have pleio- 
tropic therapeutic effects in addition to smooth mus- 
cle relaxation, such as increasing mucociliary 
transport, inhibiting mediator release (particularly 
from mast cells), suppressing endothelial permeability 
and oedema formation and modifying ganglionic 
neurotransmission. However, &agonists do not 
inhibit chronic inflammation, suggesting that the 
receptors may be uncoupled in inflamed tissues, or 
that the cells implicated in this component of the 
disease state do not contain functional 
/J,-adrenoceptors. 
TABLE 1. Percent composition of cells in airways 
samples taken using different sampling techniques 
from asthma patients. Data from Ref. 12 
Cell type 
Sampling technique 
Induced Bronchial Bronchoalveolar 
sputum wash lavage 
Epithelial 1.1 4.2 0.3 
Eosinophil 1.9 0.9 0.2 
Macrophage 30.0 90.0 93.0 
Neutrophil 36.0 1.9 0.8 
Lymphocyte 0.4 1.8 2.9 
contained the highest number of neutrophils, but 
fewer macrophages than from either of the other two 
sites. 
The induced sputum technique has been used to 
assess the different cellular responses and regulatory 
effects occurring in chronic bronchitis and asthma. A 
comparative study (13) found increased numbers of 
macrophages/monocytes, mast cells and eosinophils 
in asthma patients and increased numbers of neu- 
trophils in chronic bronchitis patients. There were 
correspondingly higher levels of GM-CSF and IL-5 in 
the fluid phase from asthma patients, and increased 
IL-8 levels in those with chronic bronchitis. 
Cellular Targets for Drug Intervention 
Strategies 
Location of corticosteroid receptors and drug 
action 
Although the anti-inflammatory action of corticoster- 
oids is well recognised clinically, the key cellular 
targets in asthma and the mechanisms at the molecu- 
lar level have yet to be established (for review see 
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Ref. 15). Mast cells, for example, lack corticosteroid 
receptors and degranulation is not inhibited by these 
agents in vitro, but both mast cell numbers and 
concentrations of inflammatory mediators, such as 
histamine and tryptase, decline during corticosteroid 
therapy in Co. Other effects of steroids include 
decreased eosinophil infiltration, probably as a result 
of modification of the cytokine profile and increased 
apoptosis. Oral prednisolone is known to decrease 
the T,2 cell population, while inhaled fluticasone 
propionate decreases immunoreactivity for IL-4 and 
IL-5, the major eosinophil regulators, in biopsy 
specimens. Lymphocytes are particularly sensitive to 
steroid regulation and exhibit decreased expression of 
the activation markers, CD25 and HLA-DR, in 
addition to reduced T,2 cytokine production. The 
effect of steroids on cell recruitment is also evident at 
the endothelial cell level, which shows decreased 
expression of the adhesion molecules involved 
in rolling margination (E and P-selectin) and in 
expression of ligands for VLA-4 and LFA-1. 
The molecular action of steroids occur at intra- 
cellular glucocorticoid receptors (GR) which are 
widely distributed in cells throughout the airways. 
Once bound to the GR, the glucocorticoid-receptor 
complex is translocated to the nucleus, where it 
interacts with the glucocorticoid-responsive element 
of target genes to modify the expression of pro- 
inflammatory cytokine production and increase the 
synthesis of other proteins such as IkB, a regulator of 
the transcription factor, nuclear factor KB (NF-KB). 
Steroids may also affect the action of other transcrip- 
tion factors known to be important in asthmatic 
inflammation, such as AP- 1. As steroids are admin- 
istered topically by inhalation, the epithelium is 
likely to be a primary target in the response. For 
example, there is evidence that cytokine-related 
epithelial events such as endothelin expression (deter- 
mined by immunohistopathology), and production 
of COX, and iNOS, are increased in asthma and 
down-regulated in asthma patients on inhaled 
steroids (16). 
Summary 
Progression of the asthmatic disease process can be 
summarised in four stages: immune activation, cell 
activation and recruitment, tissue damage, and tissue 
remodelling. 
Immune activation following allergen exposure 
results in antigen presentation by mucosal dendritic 
cells (Langerhans cells) to T-lymphocytes and their 
activation, with release of cytokines. In the primary 
response, there are T-B cell interactions with the 
production of antigen-specific IgE and subsequent 
IgE-mediated hypersensitivity reactions. The second- 
ary immune response thus involves mast cells, due to 
their cell surface expression of IgE, as well as 
T-lymphocyte responses, with both mediator and 
cytokine release. 
Structural cells of the epithelium and endothelium 
are recognised as important in the cell activation and 
recruitment processes which follow immune activa- 
tion. Leucocytes, predominantly lymphocytes and 
eosinophils, are recruited from the blood into the 
tissues, where, together with cytokine and chemokine 
production from epithelial cells and mast cells, they 
function as effecters in bronchoconstriction and 
clinical disease expression. This inflammatory process 
is thought to lead to tissue damage, particularly 
epithelial disruption, which triggers tissue remodel- 
ling, giving rise to fibroblast proliferation, collagen 
deposition, and structural changes to the smooth 
muscle and vasculature of the airways. 
Inhaled corticosteroids are particularly effective 
against chronic inflammation as they modify 
T-lymphocyte activation, decrease mast cell numbers, 
decrease epithelial and endothelial cell activation and 
reduce eosinophil recruitment. Evidence for their 
ability to reverse chronic structural changes is more 
speculative. Most studies, for example, have failed to 
find any effect of steroid therapy on the increased 
collagen deposition. However, studies on reversal of 
structural changes by anti-inflammatory therapy may 
need to be conducted over a prolonged period of 
time. 
In conclusion, in asthma there are abnormalities of 
both the large and the small airways. The standard 
tests of lung function are probably a poor guide to 
small airways disease, which can therefore be easily 
overlooked, and the contribution of small airways 
disease to clinical disease expression is poorly 
understood because of lack of availability of good 
markers. 
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